Bayer to Buy Teva’s U.S. Animal Heath Unit for $145M

The deal will close next year, if it obtains regulatory approval

By Christopher Freeburn, InvestorPlace Writer

Bayer AG‘s (PINK:BAYRY) HealthCare unit announced on Friday that it will pay about $145 million to acquire the U.S. animal health division of Teva Pharmaceuticals (NYSE:TEVA).

Under the terms of the agreement, Bayer will pay an immediate $60 million to assume control of the animal health business, Bloomberg noted. An additional $85 million will be paid as the German conglomerate realizes specified sales and production goals from the business.

Pharma Stock May Be Just What the Doctor Ordered
Pharma Stock May Be Just What the Doctor Ordered

Shares of Teva Pharmaceuticals rose fractionally in Friday morning trading, while Bayer’s shares slipped slightly in over-the-counter trading in New York.

The deal still needs approval from U.S. regulators. Assuming it receives the green light, it’s expected to be finalized in 2013.

The purchase will allow Bayer to expand animal food business in the U.S.

In June, CVS Caremark (NYSE:CVS) and Rite Aid (NYSE:RAD) sued Teva Pharmaceutical and Pfizer (NYSE:PFE) claiming that the pharmaceutical companies had conspired to prevent generic versions of Effexor XR, an antidepressant, from reaching retail stores.

Article printed from InvestorPlace Media,

©2018 InvestorPlace Media, LLC